SCOPUS 정보 검색 플랫폼

Blood

Volumn 110, Issue 10, 2007, Pages 3490-3491

Amyloidosis: Graviores morbos, asperis remedii

(1) Mehta, Jayesh a

a NORTHWESTERN UNIVERSITY (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

AMYLOIDOSIS; DRUG MEGADOSE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LOW DRUG DOSE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REVIEW; SALVAGE THERAPY; STEM CELL MOBILIZATION; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 36348945857 PISSN: 00064971 EISSN: 00064971 Source Type: Journal
DOI: 10.1182/blood-2007-08-106773 Document Type: Review

Times cited : (3)

References (8)

1
- 7244234931
- High-dose therapy for amyloidosis: The end of the beginning?
- Mehta J. High-dose therapy for amyloidosis: the end of the beginning? Blood. 2004;103:3612-3613.
- (2004) Blood , vol.103 , pp. 3612-3613
- Mehta, J.¹

2
- 36348959425
- High-dose therapy for amyloidosis
- Mehta J. High-dose therapy for amyloidosis. Blood. 2004;104:2993-2994.
- (2004) Blood , vol.104 , pp. 2993-2994
- Mehta, J.¹

3
- 33846263334
- Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
- Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109:457-464.
- (2007) Blood , vol.109 , pp. 457-464
- Wechalekar, A.D.¹ Goodman, H.J.² Lachmann, H.J.³ Offer, M.⁴ Hawkins, P.N.⁵ Gillmore, J.D.⁶

4
- 34547137414
- Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis
- Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood. 2007;110:787-788.
- (2007) Blood , vol.110 , pp. 787-788
- Palladini, G.¹ Russo, P.² Nuvolone, M.³

5
- 36348961077
- Jaccard A, Moreau P, Leblond V, et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: Results of the French multicentric randomized trial (MAG and IFM Intergroup). Blood (ASH Annual Meeting Abstracts). 2005;106:421a.
- Jaccard A, Moreau P, Leblond V, et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: Results of the French multicentric randomized trial (MAG and IFM Intergroup). Blood (ASH Annual Meeting Abstracts). 2005;106:421a.

6
- 9144269708
- High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study
- Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85-93.
- (2004) Ann Intern Med , vol.140 , pp. 85-93
- Skinner, M.¹ Sanchorawala, V.² Seldin, D.C.³

7
- 12144289675
- High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: Results of a prospective randomized trial
- Sanchorawala V, Wright DG, Seldin DC, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant. 2004;33:381-388.
- (2004) Bone Marrow Transplant , vol.33 , pp. 381-388
- Sanchorawala, V.¹ Wright, D.G.² Seldin, D.C.³

8
- 84858461477
- Liber V, accessed October 8, 2007
- Quintus Curtius Rufus. Historiarum Alexandri Magni Macedonis. Liber V. http://www.The latinlibrary.com/curtius/curtius5.shtml, accessed October 8, 2007.
- Macedonis
- Curtius Rufus, Q.¹ Alexandri Magni, H.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.